Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

ROCKVILLE, Md., May 8 /PRNewswire-FirstCall/ - Novavax Inc. (Nasdaq: NVAX) today announced financial results for the first quarter of 2009. Novavax reported a net loss of $8.3 million, or $0.12 per share, for the first quarter of 2009 compared to a net loss of $7.8 million, or $0.13 per share, for the first quarter of 2008. The Company spent a total of $7.4 million in the first quarter of 2009 and ended the quarter with $25.6 million in cash and short-term investments. During the quarter, the Company made significant progress in developing its vaccine pipeline, improved its balance sheet by raising capital and retiring a majority of its convertible debt, and completed a transaction with Cadila Pharmaceutical Limited to create a Joint Venture Company in India.

Specifically accomplishments since the 2008 year end financial results include the following:

  • Commenced development of a VLP vaccine candidate against the novel influenza A (H1N1) virus that has recently emerged in the United States and Mexico.
  • Publication of results in the Journal of Virology from preclinical studies conducted under a collaborative research and development agreement (CRADA) between the Centers for Disease Control and Prevention (CDC) and Novavax showing that an investigational H1N1 VLP vaccine based on the 1918 Spanish influenza strain protected against both the Spanish flu and a highly pathogenic H5N1 avian influenza strain.
  • Announced the initiation of enrollment in the second Phase II study of its trivalent seasonal influenza VLP vaccine candidate. This clinical trial is designed to evaluate the safety and immunogenicity of a broader range of vaccine doses and to provide data to help select doses for future studies in older adults and a Phase III efficacy study. The Company plans to report top-line immunogenicity and safety results from this study by the fourth quarte
    '/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( ... new report "Gene Therapy - Technologies, Markets and ... for gene therapy are difficult to estimate as there ... is marketed in China since ... 2014-2024. The estimates are based on epidemiology of diseases ...
(Date:9/2/2015)... Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., announced ... the multicenter Phase 2 clinical trial of NT-503 ... of recurrent subfoveal choroidal neovascularization secondary to age ... unique vascular endothelial growth factor (VEGF) receptor protein ... "This landmark proof-of-concept study will evaluate NT-503 ...
(Date:9/2/2015)... September 2, 2015 BioLight ... or the "Company"), a firm that invests in, ... cancer diagnostics, announced today that presentations highlighting its ... be delivered at the Ophthalmology Futures European Forum ... of Cataract & Refractive Surgeons ("ESCRS"), both taking ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... Staff members will be attending Pharma Ed Resources upcoming educational seminar and ... of industry leading speakers, this timely conference will provide Updates & Case Studies ...
Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3
... , , SUNNYVALE, Calif., July ... endovascular devices for the treatment of chronic total occlusions (CTOs), today ... Operating Officer. Chris previously held the position of Executive VP, Sales ... in Medical Devices including the last 2 years at FlowCardia. , ...
... LONG BRANCH, N.J., July 23 The 2009 Pharma ... the current 500 attendees and 100 exhibitors have been posted ... Alexay of Apaporis LLC, the event organizer. Attendance is ... 2008,s record turnout. One thousand attendees are expected on ...
... , SEATTLE, July 23 Cell Therapeutics, Inc. (Nasdaq ... of an underwritten public offering of 29,332,107 shares of its common ... common stock at a price to the public of $1.30 per ... common stock, for gross proceeds of approximately $38.1 million. In ...
Cached Biology Technology:FlowCardia, Inc. Appoints Chris Barys to Chief Operating Officer 2ChemOutsourcing Unveils 2009 Attendee List for September Show in New Jersey 2Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 2Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 3
(Date:8/31/2015)... , August 31, 2015 ... biometrics technology in government digitization projects to drive ... a recently published TechSci Research report, " India Biometrics Market ... India is projected to grow at a CAGR ... market is anticipated on account of extensive use of biometric ...
(Date:8/25/2015)... and BELLEVUE, Wash. , Aug. ... advanced robotic systems, announced today it will unveil its ... vehicle (UGV), at the National Tactical Officers Association Conference ... The Guardian S is the first-ever commercially available ... years of research and in-field trials and is protected ...
(Date:8/20/2015)... Calif. , Aug. 20, 2015   ... focused on improving the user experience and security ... vision technologies, today announced that its TrulySecure™ ... biometric authentication software to be FIDO Certified™. ... TrulySecure for compliance with the FIDO UAF (Universal ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... Boulder, Colo., USA New Geology science ... draws on data from several sites in the U.S., ... South Australia, Japan, the southeastern Pacific, South Africa, and ... and volcanoes are discussed. Brief highlights follow. ...
... , A Simon Fraser University chemist is the ... scientific understanding of the structure and function of ... sugars on them., PLOS ONE , an international, ... published the paper, N-glycoproteome of E14.Tg2a Mouse Embryonic ...
... traditional coffee-growing techniques may be increasing the severity of ... through plantations in Central America and Mexico, according to ... The current outbreak of coffee rust is the ... fungal disease arrived in the region more than 40 ...
Cached Biology News:The Geological Society of America Journal Geology: Dynamic geoscience 2The Geological Society of America Journal Geology: Dynamic geoscience 3The Geological Society of America Journal Geology: Dynamic geoscience 4The Geological Society of America Journal Geology: Dynamic geoscience 5The Geological Society of America Journal Geology: Dynamic geoscience 6The Geological Society of America Journal Geology: Dynamic geoscience 7The Geological Society of America Journal Geology: Dynamic geoscience 8The Geological Society of America Journal Geology: Dynamic geoscience 9The Geological Society of America Journal Geology: Dynamic geoscience 10The Geological Society of America Journal Geology: Dynamic geoscience 11The Geological Society of America Journal Geology: Dynamic geoscience 12The Geological Society of America Journal Geology: Dynamic geoscience 13The Geological Society of America Journal Geology: Dynamic geoscience 14The Geological Society of America Journal Geology: Dynamic geoscience 15Discovering cell surface proteins' behavior 2Modern growing methods may be culprit of 'coffee rust' fungal outbreak 2Modern growing methods may be culprit of 'coffee rust' fungal outbreak 3
Incomplete Adjuvant...
... Lacks the mycobacteria found in Complete Freund's Adjuvant ... Incomplete, Freund's Adjuvant is used ... used to produce water-in-oil emulsions of immunogens. ... long-lasting antibody responses which can be attributed to ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
HiTrap Streptavidin HP, 5 x 1 ml. Category: Chromatography Systems & Accessories, Systems....
Biology Products: